Stocktoria
Phio Pharmaceuticals Corp. PHIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-05-10
Phio Pharmaceuticals Corp. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $4.6M | $3.6M | $6.3M | $7.0M | $8.9M |
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M |
| EPS (diluted) | — | $-9.08 | $-46.76 | $-10.10 | $-12.43 |
| Operating cash flow | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M |
| Free cash flow | -$8.0M | -$7.1M | -$10.8M | -$12.2M | -$11.9M |
| Cash & equivalents | $21.0M | $5.4M | $8.5M | — | — |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M |
| Shareholders' equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M |
Source: SEC EDGAR filings · CIK 0001533040 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.